NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT04101357 2025-03-18
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
Phase 1/2 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT04487756 2024-04-03
VENEZO-LUNG
Instituto Oncológico Dr Rosell
Phase 1/2 Active not recruiting
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01859741 2020-09-09
PINNACLE
Mereo BioPharma
Phase 1/2 Terminated
NCT02499770 2020-08-21
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT02289690 2020-05-14
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
AbbVie
Phase 1/2 Completed
NCT01722292 2018-12-28
A Study of LY2940680 in Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT00702962 2018-10-22
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT01987232 2017-08-28
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Amgen
Phase 1/2 Completed
NCT00856830 2017-07-17
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00401609 2016-01-14
G-Step
National Cancer Institute, Naples
Phase 1/2 Completed
NCT00004186 2013-04-12
Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed